We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK Moves Toward Appraising Avastin as a Cheaper Macular Degeneration Treatment
UK Moves Toward Appraising Avastin as a Cheaper Macular Degeneration Treatment
January 19, 2011
The UK’s National Health Service (NHS) is waiting for the go-ahead to begin an appraisal for using Roche’s Avastin as a treatment for wet age-related macular degeneration (AMD), even though the biologic is not licensed for that indication.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor